Pablo Guisado-Vasco
Quironsalud
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Pablo Guisado-Vasco as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 04:48 UTC. Open this list on ClinicalTrials.gov
- Ph1/Ph2NCT05121740 · Extension Study in a Cohort of Adult Patients With COVID-19 InfectionPharmaMar · completed · COVID-19 Infection · principal investigator
Grants
NIH projects from RePORTER, fetched 2026-11-12 04:48 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.
No NIH project could be tied to this name by a shared trial or a matching institution.
Most cited trial papers
Clinical-trial papers with this author name, ranked by citations from NIH iCite, fetched 2026-11-12 04:48 UTC. The ranking covers the 200 most relevant of 4 PubMed records, and a shared surname and initials can bring in a namesake. All 4 on PubMed
- 76 citationsRCR 2.1
- Preclinical and randomized phase I studies of plitidepsin in adults hospitalized with COVID-19.Life Sci Alliance · 202239 citationsRCR 2.5
- A Phase III Randomized Controlled Trial of Plitidepsin, a Marine-Derived Compound, in Hospitalized Adults With Moderate COVID-19.Clin Infect Dis · 202412 citationsRCR 2.4
- Influence of anti-Spike protein antibody levels on tocilizumab efficacy in hospitalized patients with severe COVID-19 pneumonia: a post-hoc analysis of the COVACTA trial.BMC Infect Dis · 20252 citationsRCR 0.5